Elsevier

European Journal of Cancer

Volume 31, Issue 12, November 1995, Pages 1960-1964
European Journal of Cancer

Original paper
Male breast cancer: Results of the treatments and prognostic factors in 397 cases

https://doi.org/10.1016/0959-8049(95)00366-5Get rights and content

Abstract

From 1960 to 1986, 397 cases of non-metastatic male breast cancer (MBC) treated in 14 French regional cancer centres were reviewed. The median age was 64 years (range 25–93). TNM classification (UICC, 1978) showed seven TO, 79 T1, 162 T2, 31 T3, 74 T4 and 44 unclassified tumours (Tx). Clinical positive lymph nodes were found in 31% of the patients. 24 patients received radiotherapy only, and 373 underwent surgery, 247 of these with postoperative irradiation. Adjuvant chemotherapy and hormonal therapy were used in 71 and 68 patients, respectively. There were 382 infiltrating carcinomas and 15 pure ductal carcinoma in situ. Lymph node involvement was found in 56% of infiltrating carcinoma. The oestregen (ER) and progesterone (PgR) receptors were positive in 79% and 77%, respectively, of examined cases. Isolated local and regional recurrence were observed in 8.8% and 4.5% of cases, respectively and 40% of patients developed metastases. The crude survival rates by Kaplan-Meier method were 65% and 38% at 5 and 10 years, respectively, and the disease-specific survival rates (without death due to intercurrent disease or second cancer) was 74% at 5 years and 51% at 10 years. The disease-specific survival rate for pN- and pN+ groups were 77% and 39% at 10 years. The prognostic factors were clinical size (T) and histological axillary status (pN-/pN+). The relative risk of death for pN- was 1.0, 2.0 and 3.2 in the T0-T1, T2 and T3–T4 groups, respectively. For pN+, these relative risks increased 1.9, 3.9 and 6.0 in the same groups. The optimal treatment include modified radical mastectomy and irradiation for cases with risk factors of local relapse (nodal invasion, large tumour with cutaneous or muscular involvement). Locoregional failure had unfavourable prognosis. First-line adjuvant treatment seems to be tamoxifen, due to the very high rate of positive hormonal receptors and the old age of the patients, which contraindicate chemotherapy in many cases. The prognosis of patients with breast cancer is the same in male and female patients when disease-specific survival rate, tumour size and axillary involvement are compared.

References (32)

  • AJ Sasco et al.

    Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected etiological factors

    Int J Cancer

    (1993)
  • KS Heller et al.

    Male breast cancer: a clinicopathologic study of 97 cases

    Ann Surg

    (1978)
  • VF Guinee et al.

    The prognosis of breast cancer in males. A report of 335 cases

    Cancer

    (1993)
  • O Scheike

    Male breast cancer. 5. Clinical manifestations in 257 cases in Denmark

    Br J Cancer

    (1973)
  • C Erlichmann et al.

    Male breast cancer: a 13 year review of 89 patients

    J Clin Oncol

    (1984)
  • G Ramantanis et al.

    Breast cancer in the male: a report of 138 cases

    World J Surg

    (1980)
  • Cited by (209)

    • Triple negative apocrine carcinoma of the breast in man: Case report

      2024, Revista de Senologia y Patologia Mamaria
    • Breast Conserving Surgery Compared With Mastectomy in Male Breast Cancer: A Brief Systematic Review

      2020, Clinical Breast Cancer
      Citation Excerpt :

      The postmastectomy radiotherapy rates ranged from 8% to 61%.9,10,12,16,17 Radiotherapy after BCS was discussed in 6 studies, with mixed findings.9-11,13,14,16,17 Of the 6 studies, 5 had evaluated the outcomes for radiotherapy with the BCS and mastectomy patients combined.

    • Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients

      2017, Clinical Breast Cancer
      Citation Excerpt :

      Thus, some MBCs, particularly early stage HR+ MBC might have worse clinical outcomes than FBCs with the same stage. Male breast carcinoma has been considered similar to FBC, and MBC and FBC are currently treated similarly.3,5-8 Previously, reports of shorter OS in MBC attributed the change to older patient age and more advanced stages of disease.12,30,31

    View all citing articles on Scopus
    View full text